The USPTO issued Patent US12595269B2 to Solvonis Therapeutics Ireland Holdings Limited on April 7, 2026, covering morpholine-like monoamine releaser compounds and methods for treating CNS disorders and mental health conditions. The patent protects substituted heterocyclic bridged ring compounds including morpholine, thiomorpholine, and piperazine derivatives as alternatives to MDMA in drug-assisted therapy. This patent grant confers 20-year exclusivity rights from the February 2023 filing date.

For pharmaceutical companies and research institutions developing CNS therapeutics, this patent establishes intellectual property protection that may require licensing or design-around strategies. Competitors in the neuropsychiatric drug space should monitor this portfolio for freedom-to-operate implications, as the broad claims covering morpholine derivatives could affect related compound development programs.